Cyclacel制药 CYCC 深 沪
等待开盘 12-11 09:30:00 美东时间
0.2711
+0.001
+0.41%
华盛通- 最 高0.278
- 今 开0.2725
- 成交量 7.52万股
- 最 低 0.27
- 昨 收 0.27
- 总市值 342.75万
- 52周最高 1.17
- 市盈率 静 --
- 换手率 0.59%
- 52周最低 0.252
- 委 比 0.00%
- 总股本 1264.28万
- 历史最高 1963.20
- 量 比 0.32
- 振 幅 2.96%
- 历史最低 0.252
- 每 手 1
- 风险率 0.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cyclacel Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 EPS results.
Cyclacel Pharmaceuticals shares are trading lower after the company reported wo...
11-15 02:44
Earnings Outlook For Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is set to give its latest quarterly earn...
11-11 02:02
Cyclacel Pharmaceuticals's Earnings Outlook
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is set to give its latest quarterly earn...
08-09 01:01
奥本海默维持Cyclacel Pharmaceuticals"跑赢大盘 "建议
格隆汇5月26日丨Fintel报道，美国投资银行Oppenheimer维持对美国生物制药公司Cyclacel Pharmaceuticals(CYCC.US)的...
05-26 14:38
Recap: Cyclacel Pharmaceuticals Q1 Earnings
Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported its Q1 earnings results on Thur...
05-12 04:35
Cyclacel Pharmaceuticals Q1 EPS $(0.47) Beats $(0.66) Estimate
Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.66) by 28.79 percent. This is a 11.9 percent decrease over losses of $(0.42) per
05-12 04:31
Earnings Scheduled For May 11, 2023
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its first quarter.
05-11 21:58
Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results
BERKELEY HEIGHTS, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceutica...
05-04 21:20
Cyclacel Pharmaceuticals Announces Receipt of $4.7M R&D Tax Credit
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it received a payment of £3.9 million ($4.7 million) as a research & development (R&D) tax credit from HMRC, the tax agency of the United Kingdom government.
05-03 21:16
